Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
VANCOUVER, British Columbia, March 31, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its observance of World Lipodystrophy Day.
Chief Executive Officer Mary Szela said, "We support Lipodystrophy United (LU), the Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America (AELIP), and others in the lipodystrophy community in their mission to increase awareness and diagnosis of this serious rare disease. Education is an important step towards making an impact for people affected by lipodystrophy, many of whom are undiagnosed and inadequately treated.”
Lipodystrophy is a group of rare diseases characterized by a lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue causes a deficit in the hormone leptin leading to multiple medical issues, including severe metabolic complications.
“We strive to facilitate support for lipodystrophy patients, serving as an advocate to advance knowledge, treatment and research of lipodystrophy. World Lipodystrophy Day is an important catalyst to increase public awareness, with the goal of ultimately increasing diagnosis and treatment of this serious rare disease,” said Andra Stratton, president and founder of LU.
“World Lipodystrophy Day is an important initiative in order to raise awareness and understanding of the challenges faced by these patients and their families. Ultimately our goal is to improve diagnosis, treatment and care for those affected by this rare disease,” said Naca Eulalia Perez de Tudela Cánovas, president and founder of AELIP.
To learn more about lipodystrophy, visit www.aelip.org, www.lipodystrophyunited.org or http://www.lipodystrophy.co.uk.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Novelion Therapeutics Inc. Amanda Murphy Director, Investor Relations & Corporate Communications 857-242-5024
